한글목차

CAR T세포치료 시장은 2021년에 17억 달러로 평가되며, 2022-2031년 CAGR 13.5%로 성장하며, 2031년까지 61억 달러에 달할 것으로 추정됩니다.

CAR T 세포 치료는 새로운 유형의 암 치료법입니다. CAR T 세포 치료는 세포 기반 유전자 치료의 일종으로, T 세포의 유전자를 변형시켜 암을 공격하기 쉽도록 T 세포의 유전자를 변경하여 T 세포가 암을 공격할 수 있도록 면역 체계의 일부인 백혈구의 일종인 T 세포를 재프로그래밍하는 치료법이다, 표면에 수용체 역할을 하는 단백질을 가지고 있습니다. 의료 전문가들은 현재 CAR T 세포 치료를 다양한 유형의 암 치료에 사용하고 있습니다.

CAR T 세포 치료 시장은 암 유병률 증가, 암 치료에 이상적인 치료제에 대한 수요 증가, 일부 국가에서 제조업체 및 보험 프로바이더가 제공하는 유리한 상환 정책으로 인해 예측 기간 중 큰 시장 성장을 보일 것으로 예상됩니다. 그러나 높은 치료 비용과 이러한 치료제의 승인에 대한 정부의 엄격한 규제는 시장 성장에 걸림돌이 될 것으로 예상됩니다. 또한 파이프라인에 있는 유망한 약물, 새로운 CART 치료제의 승인 기대, 이상적인 치료법이 없는 대상 인구 증가, CART 요법에 대한 인식의 급격한 증가는 예측 기간 중 시장 성장을 크게 촉진할 것으로 예상됩니다. 또한 기술 발전, 다양한 제품 출시, 인수, 제휴, 계약 등 주요 기업 간 전략도 중요한 요인으로 작용할 것으로 보입니다.

CAR T 세포 치료제 시장은 약물 유형, 적응증, 최종사용자, 지역별로 분류됩니다. 약물 유형에 따라 시장은 엑시카부타젠 실로로이셀, 티사젠 로로이셀, 브렉스카부타젠 오토로이셀, 기타로 분류됩니다. 적응증별로는 림프종, 급성 림프성 백혈병, 기타로 분류됩니다. 최종사용자에 따라 병원과 암 치료 센터로 세분화됩니다.

CAR T세포치료 시장은 북미(미국, 캐나다), 유럽(독일, 프랑스, 영국, 기타 유럽 지역), 아시아태평양(일본, 중국, 기타 아시아태평양), 라틴아메리카(중남미, 기타 중동 아프리카)에서 조사되고 있습니다.

본 리포트에 게재되어 있는 주요 기업은 다음과 같습니다. Autolus사, Bluebird Bio-Inc.회사, Bristol-Myers Squibb사, Caribou Biosciences Inc.회사, Cartesian Therapeutics사, Celgene Corporation사, Cellectis사, Celyad사, Gilead Sciences사(Kite Pharma Inc.회사), Intellia Therapeutics사, Juno Therapeutics사, Merck &Co.Inc., Miltenyi Biotech, Novartis AG, Pfizer Inc., Sorrento Therapeutics, Inc.

목차

제1장 서론

제2장 주요 요약

제3장 시장 개요

• 시장의 정의와 범위
• 주요 조사 결과
  • 영향요인
  • 주요 투자 기회
• Porter's Five Forces 분석
• 시장 역학
  • 촉진요인
    • 암이환율의 급증
    • CAR T세포치료에 대한 의식의 향상
    • 암치료에서 이상적인 치료제의 수요 증가
  • 억제요인
    • CAR T세포치료에 드는 고비용
    • 의약품 승인에 대한 정부의 엄격한 규제
  • 기회
    • CAR T 세포치료제 개발을 위한 연구개발 활동의 증가
• COVID-19 시장에 대한 영향 분석

제4장 CAR T세포치료 시장 : 약제 유형별

• 개요
• Axicabtagene Ciloleucel
• Tisagenlecleucel
• Brexucabtagene Autoleucel
• 기타

제5장 CAR T세포치료 시장 : 적응증별

• 개요
• 림프종
• 급성 림프구성 백혈병
• 기타

제6장 CAR T세포치료 시장 : 최종사용자별

• 개요
• 병원
• 암치료 센터

제7장 CAR T세포치료 시장 : 지역별

• 개요
• 북미
  • 미국
  • 캐나다
• 유럽
  • 독일
  • 프랑스
  • 영국
  • 기타
• 아시아태평양
  • 일본
  • 중국
  • 기타
• 라틴아메리카·중동 및 아프리카
  • 라틴아메리카
  • 중동 및 아프리카

제8장 경쟁 구도

• 서론
• 주요 성공 전략
• 주요 10사의 제품 매핑
• 경쟁 대시보드
• 경쟁 히트맵
• 주요 기업의 포지셔닝(2021년)

제9장 기업 개요

• Autolus Therapeutics
• Bluebird Bio, Inc.
• Bristol-Myers Squibb
• Caribou Biosciences, Inc.
• Cartesian Therapeutics, Inc.
• Celgene Corporation
• Cellectis
• Celyad Oncology
• Gilead Sciences, Inc.(Kite Pharma Inc.)
• Intellia Therapeutics
• Juno Therapeutics, Inc.
• Merck & Co., Inc.
• Miltenyi Biotech
• Novartis AG
• Pfizer, Inc.
• Sorrento Therapeutics, Inc.

영문목차

According to a new report published by Allied Market Research, titled, "CAR T-Cell therapy Market," The car t-cell therapy market was valued at $1.7 billion in 2021, and is estimated to reach $6.1 billion by 2031, growing at a CAGR of 13.5% from 2022 to 2031. Chimeric antigen receptor (CAR) T-cell therapy is a new type of cancer treatment. CAR T-cell therapy is a type of cell-based gene therapy, because it involves altering the genes inside T-cells to help them attack the cancer. T-cells are part of the immune system. They are a type of white blood cell with proteins on the surface that act as receptors.

Chimeric antigen receptor (CAR) T-cell therapy is a new type of cancer treatment. During this treatment, healthcare professionals reprogram the immune system to attack cancer cells. CAR T-cell therapy is a type of cell-based gene therapy, because it involves altering the genes inside T-cells to help them attack the cancer. T-cells are part of the immune system. They are a type of white blood cell with proteins on the surface that act as receptors. Healthcare professionals currently use CAR T-cell therapy to treat various types of cancer.

The CAR T-cell therapy market will show significant market growth during the forecast period owing to rise in prevalence of cancer, rise in demand for ideal therapeutics for treatment of cancer, and favorable reimbursement policies provided by manufacturers & insurance providers in some countries. However, higher cost of treatment, and stringent government regulation for approval of these therapeutics are expected to hamper the market growth. Furthermore, promising drugs in pipeline, expected approval of newer CART therapeutics, rise in number of target population with lack of ideal treatment, and surge in awareness regarding CART therapies are expected to significantly drive the market growth during the forecast period. In addition, technological advancements, launch of various products, and strategies among the key players such as acquisition, collaboration, and agreement drive the CAR T-cell therapy market growth.

The CAR T-cell therapy market is segmented on the basis of drug type, indication, end user, and region. On the basis of drug type, the market is classified into axicabtagene ciloleucel, tisagenlecleucel, brexucabtagene autoleucel, and others. By indication, the market is segregated into lymphoma, acute lymphocytic leukemia, and others. Depending on end user, it is fragmented into hospitals and cancer treatment centers.

The CAR T-cell therapy market is studied across North America (the U.S., and Canada), Europe (Germany, France, the UK, and rest of Europe), Asia-Pacific (Japan, China, and rest of Asia-Pacific), and LAMEA (Latin America and Middle East and Africa).

The major players profiled in the report are: Autolus, Bluebird Bio-Inc., Bristol-Myers Squibb, Caribou Biosciences Inc., Cartesian Therapeutics, Celgene Corporation, Cellectis, Celyad, Gilead Sciences, Inc. (Kite Pharma Inc.), Intellia Therapeutics, Juno Therapeutics, Merck & Co. Inc., Miltenyi Biotech, Novartis AG, Pfizer Inc., and Sorrento Therapeutics, Inc.

Key Benefits For Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the car t-cell therapy market analysis from 2021 to 2031 to identify the prevailing car t-cell therapy market opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the car t-cell therapy market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global car t-cell therapy market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

• Quarterly Update and* (only available with a corporate license, on listed price)
• 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
• Free Upcoming Version on the Purchase of Five and Enterprise User License.
• 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
• 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
• Free data Pack on the Five and Enterprise User License. (Excel version of the report)
• Free Updated report if the report is 6-12 months old or older.
• 24-hour priority response*
• Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

• Go To Market Strategy
• New Product Development/ Product Matrix of Key Players
• Additional company profiles with specific to client's interest
• Additional country or region analysis- market size and forecast
• Average Selling Price Analysis / Price Point Analysis
• Key player details (including location, contact details, supplier/vendor network etc. in excel format)
• SWOT Analysis

Key Market Segments

By Drug type

• Axicabtagene Ciloleucel
• Tisagenlecleucel
• Brexucabtagene Autoleucel
• Others

By Indication

• Lymphoma
• Acute Lymphocytic Leukemia
• Others

By End user

• Hospitals
• Cancer Treatment Centers

By Region

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • U.K.
  • Rest of Europe
• Asia-Pacific
  • Japan
  • China
  • Rest of Asia-Pacific
• LAMEA
  • Latin America
  • Middle East And Africa

Key Market Players:

• Autolus Therapeutics
• Bluebird Bio, Inc.
• Bristol-Myers Squibb
• Caribou Biosciences, Inc.
• Cartesian Therapeutics, Inc.
• Celgene Corporation
• Cellectis
• Celyad Oncology
• Gilead Sciences, Inc. (Kite Pharma Inc.)
• Intellia Therapeutics
• Juno Therapeutics, Inc.
• Merck & Co., Inc.
• Miltenyi Biotech
• Novartis AG
• Pfizer, Inc.
• Sorrento Therapeutics, Inc.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

• 1.1. Report description
• 1.2. Key market segments
• 1.3. Key benefits to the stakeholders
• 1.4. Research Methodology
  • 1.4.1. Primary research
  • 1.4.2. Secondary research
  • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

• 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

• 3.1. Market definition and scope
• 3.2. Key findings
  • 3.2.1. Top impacting factors
  • 3.2.2. Top investment pockets
• 3.3. Porter's five forces analysis
  • 3.3.1. Low bargaining power of suppliers
  • 3.3.2. Low threat of new entrants
  • 3.3.3. Low threat of substitutes
  • 3.3.4. Low intensity of rivalry
  • 3.3.5. Low bargaining power of buyers
• 3.4. Market dynamics
  • 3.4.1. Drivers
    • 3.4.1.1. Surge in prevalence of cancer
    • 3.4.1.2. Rise in awareness regarding CAR T-cell therapy
    • 3.4.1.3. Increase in demand of ideal therapeutics for treatment of cancer

• 3.4.2. Restraints
  • 3.4.2.1. High cost of CAR T-cell therapies
  • 3.4.2.2. Strict government regulation for approval of drugs

• 3.4.3. Opportunities
  • 3.4.3.1. Increase in R&D activities to develop CAR T-cell therapeutics

• 3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: CAR T-CELL THERAPY MARKET, BY DRUG TYPE

• 4.1. Overview
  • 4.1.1. Market size and forecast
• 4.2. Axicabtagene Ciloleucel
  • 4.2.1. Key market trends, growth factors and opportunities
  • 4.2.2. Market size and forecast, by region
  • 4.2.3. Market share analysis by country
• 4.3. Tisagenlecleucel
  • 4.3.1. Key market trends, growth factors and opportunities
  • 4.3.2. Market size and forecast, by region
  • 4.3.3. Market share analysis by country
• 4.4. Brexucabtagene Autoleucel
  • 4.4.1. Key market trends, growth factors and opportunities
  • 4.4.2. Market size and forecast, by region
  • 4.4.3. Market share analysis by country
• 4.5. Others
  • 4.5.1. Key market trends, growth factors and opportunities
  • 4.5.2. Market size and forecast, by region
  • 4.5.3. Market share analysis by country

CHAPTER 5: CAR T-CELL THERAPY MARKET, BY INDICATION

• 5.1. Overview
  • 5.1.1. Market size and forecast
• 5.2. Lymphoma
  • 5.2.1. Key market trends, growth factors and opportunities
  • 5.2.2. Market size and forecast, by region
  • 5.2.3. Market share analysis by country
• 5.3. Acute Lymphocytic Leukemia
  • 5.3.1. Key market trends, growth factors and opportunities
  • 5.3.2. Market size and forecast, by region
  • 5.3.3. Market share analysis by country
• 5.4. Others
  • 5.4.1. Key market trends, growth factors and opportunities
  • 5.4.2. Market size and forecast, by region
  • 5.4.3. Market share analysis by country

CHAPTER 6: CAR T-CELL THERAPY MARKET, BY END USER

• 6.1. Overview
  • 6.1.1. Market size and forecast
• 6.2. Hospitals
  • 6.2.1. Key market trends, growth factors and opportunities
  • 6.2.2. Market size and forecast, by region
  • 6.2.3. Market share analysis by country
• 6.3. Cancer Treatment Centers
  • 6.3.1. Key market trends, growth factors and opportunities
  • 6.3.2. Market size and forecast, by region
  • 6.3.3. Market share analysis by country

CHAPTER 7: CAR T-CELL THERAPY MARKET, BY REGION

• 7.1. Overview
  • 7.1.1. Market size and forecast By Region
• 7.2. North America
  • 7.2.1. Key trends and opportunities
  • 7.2.2. Market size and forecast, by Drug type
  • 7.2.3. Market size and forecast, by Indication
  • 7.2.4. Market size and forecast, by End user
  • 7.2.5. Market size and forecast, by country
    • 7.2.5.1. U.S.
    • 7.2.5.1.1. Key market trends, growth factors and opportunities
    • 7.2.5.1.2. Market size and forecast, by Drug type
    • 7.2.5.1.3. Market size and forecast, by Indication
    • 7.2.5.1.4. Market size and forecast, by End user
    • 7.2.5.2. Canada
    • 7.2.5.2.1. Key market trends, growth factors and opportunities
    • 7.2.5.2.2. Market size and forecast, by Drug type
    • 7.2.5.2.3. Market size and forecast, by Indication
    • 7.2.5.2.4. Market size and forecast, by End user
• 7.3. Europe
  • 7.3.1. Key trends and opportunities
  • 7.3.2. Market size and forecast, by Drug type
  • 7.3.3. Market size and forecast, by Indication
  • 7.3.4. Market size and forecast, by End user
  • 7.3.5. Market size and forecast, by country
    • 7.3.5.1. Germany
    • 7.3.5.1.1. Key market trends, growth factors and opportunities
    • 7.3.5.1.2. Market size and forecast, by Drug type
    • 7.3.5.1.3. Market size and forecast, by Indication
    • 7.3.5.1.4. Market size and forecast, by End user
    • 7.3.5.2. France
    • 7.3.5.2.1. Key market trends, growth factors and opportunities
    • 7.3.5.2.2. Market size and forecast, by Drug type
    • 7.3.5.2.3. Market size and forecast, by Indication
    • 7.3.5.2.4. Market size and forecast, by End user
    • 7.3.5.3. U.K.
    • 7.3.5.3.1. Key market trends, growth factors and opportunities
    • 7.3.5.3.2. Market size and forecast, by Drug type
    • 7.3.5.3.3. Market size and forecast, by Indication
    • 7.3.5.3.4. Market size and forecast, by End user
    • 7.3.5.4. Rest of Europe
    • 7.3.5.4.1. Key market trends, growth factors and opportunities
    • 7.3.5.4.2. Market size and forecast, by Drug type
    • 7.3.5.4.3. Market size and forecast, by Indication
    • 7.3.5.4.4. Market size and forecast, by End user
• 7.4. Asia-Pacific
  • 7.4.1. Key trends and opportunities
  • 7.4.2. Market size and forecast, by Drug type
  • 7.4.3. Market size and forecast, by Indication
  • 7.4.4. Market size and forecast, by End user
  • 7.4.5. Market size and forecast, by country
    • 7.4.5.1. Japan
    • 7.4.5.1.1. Key market trends, growth factors and opportunities
    • 7.4.5.1.2. Market size and forecast, by Drug type
    • 7.4.5.1.3. Market size and forecast, by Indication
    • 7.4.5.1.4. Market size and forecast, by End user
    • 7.4.5.2. China
    • 7.4.5.2.1. Key market trends, growth factors and opportunities
    • 7.4.5.2.2. Market size and forecast, by Drug type
    • 7.4.5.2.3. Market size and forecast, by Indication
    • 7.4.5.2.4. Market size and forecast, by End user
    • 7.4.5.3. Rest of Asia-Pacific
    • 7.4.5.3.1. Key market trends, growth factors and opportunities
    • 7.4.5.3.2. Market size and forecast, by Drug type
    • 7.4.5.3.3. Market size and forecast, by Indication
    • 7.4.5.3.4. Market size and forecast, by End user
• 7.5. LAMEA
  • 7.5.1. Key trends and opportunities
  • 7.5.2. Market size and forecast, by Drug type
  • 7.5.3. Market size and forecast, by Indication
  • 7.5.4. Market size and forecast, by End user
  • 7.5.5. Market size and forecast, by country
    • 7.5.5.1. Latin America
    • 7.5.5.1.1. Key market trends, growth factors and opportunities
    • 7.5.5.1.2. Market size and forecast, by Drug type
    • 7.5.5.1.3. Market size and forecast, by Indication
    • 7.5.5.1.4. Market size and forecast, by End user
    • 7.5.5.2. Middle East And Africa
    • 7.5.5.2.1. Key market trends, growth factors and opportunities
    • 7.5.5.2.2. Market size and forecast, by Drug type
    • 7.5.5.2.3. Market size and forecast, by Indication
    • 7.5.5.2.4. Market size and forecast, by End user

CHAPTER 8: COMPETITIVE LANDSCAPE

• 8.1. Introduction
• 8.2. Top winning strategies
• 8.3. Product Mapping of Top 10 Player
• 8.4. Competitive Dashboard
• 8.5. Competitive Heatmap
• 8.6. Top player positioning, 2021

CHAPTER 9: COMPANY PROFILES

• 9.1. Autolus Therapeutics
  • 9.1.1. Company overview
  • 9.1.2. Key Executives
  • 9.1.3. Company snapshot
  • 9.1.4. Operating business segments
  • 9.1.5. Product portfolio
• 9.2. Bluebird Bio, Inc.
  • 9.2.1. Company overview
  • 9.2.2. Key Executives
  • 9.2.3. Company snapshot
  • 9.2.4. Operating business segments
  • 9.2.5. Product portfolio
  • 9.2.6. Business performance
  • 9.2.7. Key strategic moves and developments
• 9.3. Bristol-Myers Squibb
  • 9.3.1. Company overview
  • 9.3.2. Key Executives
  • 9.3.3. Company snapshot
  • 9.3.4. Operating business segments
  • 9.3.5. Product portfolio
  • 9.3.6. Business performance
  • 9.3.7. Key strategic moves and developments
• 9.4. Caribou Biosciences, Inc.
  • 9.4.1. Company overview
  • 9.4.2. Key Executives
  • 9.4.3. Company snapshot
  • 9.4.4. Operating business segments
  • 9.4.5. Product portfolio
• 9.5. Cartesian Therapeutics, Inc.
  • 9.5.1. Company overview
  • 9.5.2. Key Executives
  • 9.5.3. Company snapshot
  • 9.5.4. Operating business segments
  • 9.5.5. Product portfolio
• 9.6. Celgene Corporation
  • 9.6.1. Company overview
  • 9.6.2. Key Executives
  • 9.6.3. Company snapshot
  • 9.6.4. Operating business segments
  • 9.6.5. Product portfolio
• 9.7. Cellectis
  • 9.7.1. Company overview
  • 9.7.2. Key Executives
  • 9.7.3. Company snapshot
  • 9.7.4. Operating business segments
  • 9.7.5. Product portfolio
  • 9.7.6. Business performance
  • 9.7.7. Key strategic moves and developments
• 9.8. Celyad Oncology
  • 9.8.1. Company overview
  • 9.8.2. Key Executives
  • 9.8.3. Company snapshot
  • 9.8.4. Operating business segments
  • 9.8.5. Product portfolio
  • 9.8.6. Key strategic moves and developments
• 9.9. Gilead Sciences, Inc. (Kite Pharma Inc.)
  • 9.9.1. Company overview
  • 9.9.2. Key Executives
  • 9.9.3. Company snapshot
  • 9.9.4. Operating business segments
  • 9.9.5. Product portfolio
  • 9.9.6. Business performance
  • 9.9.7. Key strategic moves and developments
• 9.10. Intellia Therapeutics
  • 9.10.1. Company overview
  • 9.10.2. Key Executives
  • 9.10.3. Company snapshot
  • 9.10.4. Operating business segments
  • 9.10.5. Product portfolio
• 9.11. Juno Therapeutics, Inc.
  • 9.11.1. Company overview
  • 9.11.2. Key Executives
  • 9.11.3. Company snapshot
  • 9.11.4. Operating business segments
  • 9.11.5. Product portfolio
• 9.12. Merck & Co., Inc.
  • 9.12.1. Company overview
  • 9.12.2. Key Executives
  • 9.12.3. Company snapshot
  • 9.12.4. Operating business segments
  • 9.12.5. Product portfolio
  • 9.12.6. Business performance
• 9.13. Miltenyi Biotech
  • 9.13.1. Company overview
  • 9.13.2. Key Executives
  • 9.13.3. Company snapshot
  • 9.13.4. Operating business segments
  • 9.13.5. Product portfolio
• 9.14. Novartis AG
  • 9.14.1. Company overview
  • 9.14.2. Key Executives
  • 9.14.3. Company snapshot
  • 9.14.4. Operating business segments
  • 9.14.5. Product portfolio
  • 9.14.6. Business performance
• 9.15. Pfizer, Inc.
  • 9.15.1. Company overview
  • 9.15.2. Key Executives
  • 9.15.3. Company snapshot
  • 9.15.4. Operating business segments
  • 9.15.5. Product portfolio
  • 9.15.6. Business performance
• 9.16. Sorrento Therapeutics, Inc.
  • 9.16.1. Company overview
  • 9.16.2. Key Executives
  • 9.16.3. Company snapshot
  • 9.16.4. Operating business segments
  • 9.16.5. Product portfolio
  • 9.16.6. Business performance